How local breast cancer treatments affect side effects and quality of life in Chinese patients
A Prospective Multi-modal Cohort Study of Local Treatment-related Toxicities and Quality of Life in Chinese Breast Cancer Patients (PERSEVERE)
This project will test how surgery and related treatments (chemotherapy, radiation, hormone or targeted therapy) affect side effects and daily quality of life for people with early-stage breast cancer in China.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 3 sites (Beijing, Beijing Municipality and 2 other locations) |
| Trial ID | NCT07010939 on ClinicalTrials.gov |
What this trial studies
PERSEVERE is a prospective, multi-center cohort that follows people with stage I–III breast cancer who are receiving surgery and/or neoadjuvant or adjuvant therapies. Participants complete regular patient-reported outcome questionnaires and undergo clinical checks such as heart imaging, lung function tests, routine labs, and blood and tissue sample collection. The study tracks short- and long-term physical, psychological, and social effects of treatment to map patterns of toxicity and recovery. Data will be used to link clinical tests and biomarkers with reported symptoms and quality-of-life changes over time.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 or older with newly diagnosed stage I–III invasive breast cancer in China who have not completed curative treatment and are planning surgery and/or neoadjuvant or adjuvant therapy and can complete questionnaires and follow-up visits.
Not a fit: People with metastatic disease or local recurrence, those who have already finished curative treatment, recent other cancers, or who are pregnant or breastfeeding are unlikely to benefit from joining.
Why it matters
Potential benefit: If successful, the findings could help clinicians tailor treatments and supportive care to reduce side effects and improve daily functioning for people with early breast cancer.
How similar studies have performed: Prior prospective cohorts and patient-reported outcome studies have identified common treatment toxicities and quality-of-life patterns, but few large multi-center Chinese cohorts have combined long-term PROs with detailed cardiac and pulmonary testing.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women aged 18 years or older * Diagnosed with stage I, II, or III invasive breast cancer confirmed by pathology or cytology * No signs of metastatic disease (cancer that has spread to other parts of the body) * Scheduled to receive local treatment, including: Surgery And/or neoadjuvant or adjuvant therapy such as chemotherapy, radiation, hormone therapy, or targeted therapy * Willing and able to complete health questionnaires and attend follow-up visits * Has given written informed consent to join the study Exclusion Criteria: * Have metastatic breast cancer or local recurrence * Have already received curative treatment (surgery, chemo, etc.) for the current breast cancer before joining the study * Are currently pregnant or breastfeeding * Have a history of another cancer within the past 5 years (except for non-melanoma skin cancer or in-situ cervical cancer) * Are unable to participate in the study due to mental, physical, or legal reasons (for example, under legal guardianship or imprisonment)
Where this trial is running
Beijing, Beijing Municipality and 2 other locations
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Beijing Municipality, China (Recruiting)
- Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center — Shenzhen, Guangdong, China (Active_not_recruiting)
- Shanxi Cancer Hospital — Taiyuan, Shanxi, China (Active_not_recruiting)
Study contacts
- Principal investigator: Yi Fang, MD — National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Study coordinator: Zheng Qu, MD
- Email: quzheng1237@gmail.com
- Phone: +8615010998669
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.